Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2025; 13(2): 96876
Published online Jan 16, 2025. doi: 10.12998/wjcc.v13.i2.96876
Published online Jan 16, 2025. doi: 10.12998/wjcc.v13.i2.96876
Pan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions: A case report
Seungmee Lee, Yu-Ra Jeon, Changmin Shin, Sojin Shin, Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu 42601, South Korea
Sun-Young Kwon, Department of Pathology and Institute for Cancer Research, Keimyung University School of Medicine, Daegu 42601, South Korea
Author contributions: Lee S and Shin S contributed to the conception and design of the case report; Lee S, Shin C and Kwon SY collected and analyzed the case data; Kwon SY and Shin S provided critical resources and supervision; Lee S, Jeon YR, Kwon SY, and Shin S wrote and edited the manuscript; All authors have read and approved the final manuscript.
Supported by Grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea, No. RS-2022-KH129889.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this study and accompanying images.
Conflict-of-interest statement: All authors declare that there is no conflict of interest regarding the publication of this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sojin Shin, MD, PhD, Professor, Department of Obstetrics and Gynecology, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu 42601, South Korea. hope2014@dsmc.or.kr
Received: May 17, 2024
Revised: October 15, 2024
Accepted: October 24, 2024
Published online: January 16, 2025
Processing time: 174 Days and 16.1 Hours
Revised: October 15, 2024
Accepted: October 24, 2024
Published online: January 16, 2025
Processing time: 174 Days and 16.1 Hours
Core Tip
Core Tip: This case report highlights a rare malignant mesenchymal tumor originating from the uterine cervix that was pan-TRK immunohistochemistry-positive but lacked neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Although NTRK-fusion sarcomas are aggressive and may benefit from targeted TRK inhibitor therapy, this case underscores the importance of molecular genetic diagnostics to guide accurate treatment decisions. The report contributes to the limited literature on NTRK-positive uterine sarcomas and emphasizes the potential clinical value of TRK inhibitors in selected cases.